Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies
that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Background—Three types of anthracycline-induced cardiotoxicities are currently
recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patients.
The mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood …

Aims Cardiac biomarkers are a mainstay in diagnosis of cardiovascular disease but their
role in cardio‐oncology has not yet been systematically evaluated. This meta‐analysis aims …